研究单位：[1]Shanghai LianBio Development Co., Ltd.[2]Beijing Cancer Hospital ( Department of Thoracic Oncology ),Beijing,Beijing,China,100142[3]Beijing Cancer Hospital (Department of Gynecological Oncology),Beijing,Beijing,China,100142[4]Beijing Cancer Hospital,Beijing,Beijing,China,100142[5]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[6]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[7]The Sixth Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510655[8]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071030[9]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[10]Hubei Cancer Hospital,Wuan,Hubei,China,430079[11]The First People's Hospital of Changzhou,Changzhou,Jiangsu,China,213004[12]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China,210008[13]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China,110042[14]Zhongshan Hospital Fudan University,Shanghai,Shanghai,China,200032[15]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China,030013[16]The First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[17]Sir Run Run Shaw hospital, Zhejiang University school of Medicine,Hangzhou,Zhejiang,China,310016[18]Henan Cancer Hospital,Henan,Zhengzhou,China,450008
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 1-3. This is a multicenter, open-label, single arm phase IIa study to evaluate the efficacy and safety of Infigratinib in subjects with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 genetic amplification or other advanced solid tumors with other FGFR genetic alternations who have failed in 2nd line or above treatment. This trial includes 2 cohorts (i.e., baskets) with above mentioned indications.
